Researchers at the University of South Florida have focused on the demyelination hallmark of traumatic brain injury (TBI) and have tested a liver X receptor (LXR) agonist, GW-3965, for the potential treatment of it. Activation of LXRs is known to support oligodendrocyte maturation, increase myelin gene expression and promote remyelination.
Neural stem cell-derived exosomes (Nexo) are small, membrane-bound extracellular vesicles secreted by neural stem cells. Due to their role in cell-to-cell communication within the central nervous system (CNS), they are considered a promising strategy for modulating neuronal function and promoting repair processes in conditions such as stroke, traumatic brain injury and neurodegenerative diseases. Researchers at the Chinese Academy of Sciences developed an advanced Nexo platform incorporating ultrasmall nanoselenium via lipid-mediated nucleation, termed Senexo.
In what represents their first patenting, researchers from New York’s Stony Brook University filed for protection for development of a system and method that uses computer vision to analyze microscale facial movements in order to objectively help diagnose, monitor, and treat disorders of consciousness.
Researchers from The Ohio State University have filed for protection of Neurothread, a wire-type neurotransmitter-sensing platform that utilizes the cross-section of commercially available ultrathin microwires as microelectrodes.
In what represents the first patenting from Cerathrive Ltd., its co-founder and CEO, Sarah Turner, describes their development of the Cera system, which they claim to be the first and only U.S. FDA-cleared red-light device that targets the gut-brain axis to improve focus and energy levels.
Researchers from Arizona State University and Mayo Clinic have filed for protection of wireless, battery-free brain implants which may be used in the monitoring, stimulation, and treatment of epilepsy, tumors, neurodegenerative disorders, neuroinflammatory conditions and trauma.
In what represents its first patenting, PBSF Inc. filed for protection of brain monitoring and neuroprotection strategies for infants at high risk on a large scale.
Laboratory Corp. of America Holdings introduced a glial fibrillary acidic protein blood-based test available commercially in the U.S. for the early detection of neurodegenerative diseases and brain injuries. The test, which the company said was the first of its kind, is designed to assess the presence and progression of Alzheimer’s disease, multiple sclerosis, glioblastoma and traumatic brain injury.
It’s game time for Abbott Laboratories’ 15-minute concussion test now that FDA clearance is in hand. The I-Stat traumatic brain injury cartridge uses whole blood, allowing bedside assessment of patients without lab processing.
